Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

VJVirtual | Hematological malignancy amid COVID-19

Naval Daver • 18 Apr 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia General Leukemia Venetoclax

Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how the COVID-19 pandemic is impacting the treatment of patients with hematological malignancy and what is being done to combat issues that have arisen. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Naval Daver

Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study 2:30
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Naval Daver • 8 Dec 2025
The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
Approaches to managing FLT3-mutant AML 12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025

Related Videos

HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML 8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
POD36 as a prognostic marker and clinical tool in frontline CLL 3:03
POD36 as a prognostic marker and clinical tool in frontline CLL
Paul Hampel • 8 Dec 2025
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology 7:37
AI‑driven virtual tumor board enhances precision care in AML: refining AI use in hematology
David Swoboda • 5 Dec 2025
Recent advancements in the understanding of Richter’s transformation 1:00
Recent advancements in the understanding of Richter’s transformation
Elisa ten Hacken • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals